Fig. 1
From: MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Progression-free survival. a Investigator-assessed and b Independent central review in the intent-to-treat population. NR, not reached
Fig. 1 | npj Breast Cancer
